- Research article
- Open Access
Rapid assessment of the effect of ciprofloxacin on chromosomal DNA from Escherichia coli using an in situ DNA fragmentation assay
© Tamayo et al; licensee BioMed Central Ltd. 2009
- Received: 13 November 2008
- Accepted: 13 April 2009
- Published: 13 April 2009
Fluoroquinolones are extensively used antibiotics that induce DNA double-strand breaks (DSBs) by trapping DNA gyrase and topoisomerase IV on DNA. This effect is usually evaluated using biochemical or molecular procedures, but these are not effective at the single-cell level. We assessed ciprofloxacin (CIP)-induced chromosomal DNA breakage in single-cell Escherichia coli by direct visualization of the DNA fragments that diffused from the nucleoid obtained after bacterial lysis in an agarose microgel on a slide.
Exposing the E. coli strain TG1 to CIP starting at a minimum inhibitory concentration (MIC) of 0.012 μg/ml and at increasing doses for 40 min increased the DNA fragmentation progressively. DNA damage started to be detectable at the MIC dose. At a dose of 1 μg/ml of CIP, DNA damage was visualized clearly immediately after processing, and the DNA fragmentation increased progressively with the antibiotic incubation time. The level of DNA damage was much higher when the bacteria were taken from liquid LB broth than from solid LB agar. CIP treatment produced a progressively slower rate of DNA damage in bacteria in the stationary phase than in the exponentially growing phase. Removing the antibiotic after the 40 min incubation resulted in progressive DSB repair activity with time. The magnitude of DNA repair was inversely related to CIP dose and was noticeable after incubation with CIP at 0.1 μg/ml but scarce after 10 μg/ml. The repair activity was not strictly related to viability. Four E. coli strains with identified mechanisms of reduced sensitivity to CIP were assessed using this procedure and produced DNA fragmentation levels that were inversely related to MIC dose, except those with very high MIC dose.
This procedure for determining DNA fragmentation is a simple and rapid test for studying and evaluating the effect of quinolones.
- Minimum Inhibitory Concentration
- Luria Bertani
- Nucleotide Excision Repair
Fluoroquinolones are broad-spectrum antibacterial agents that are used widely to treat a variety of infections, such as gonococcal infections, osteomyelitis, enteric, and respiratory and urinary tract infections. Ciprofloxacin (CIP) is one of the most consumed fluoroquinolones worldwide [1, 2]. The type II topoisomerases DNA gyrase and topoisomerase IV are the target of quinolones [3, 4]. DNA gyrase is the preferential target in gram-negative bacteria such as E. coli, whereas topoisomerase IV is affected mainly in gram-positive bacteria . These enzymes induce transient DNA double-strand breaks (DSBs) on bacterial chromosomes, which either introduce negative supercoiling, as in the case of DNA gyrase, or relax supercoiling and decatenate-replicated daughter chromosomes, as in the case of topoisomerase IV [3–5]. DNA gyrase is a tetramer with two GyrA and two GyrB subunits, and topoisomerase IV comprises two ParC and two ParE subunits. After DSB induction, the topoisomerase passes through the DNA duplex, seals the break, and releases DNA. During this process, a transient covalent link is established between the GyrA or the ParC subunits and the 5' end of each DNA break [3, 5].
Quinolones bind rapidly to the DNA topoisomerases attached to DNA, producing ternary complexes comprising quinolone-topoisomerase-DNA. These complexes promptly block DNA replication and RNA transcription, an action that inhibits cell growth but does not clearly explain the cell killing by quinolones [5–7]. After formation of the ternary complex, a DSB is produced by topoisomerase, but bound quinolone inhibits the subsequent ligation of the DNA ends by trapping the topoisomerase on DNA to the GyrA or ParC proteins through a covalent bond of the 5' ends. These products are called cleaved complexes and are distributed throughout the bacterial chromosome. When using first-generation quinolones such us nalidixic acid, DSBs are constrained initially by the proteins from the cleaved complexes, and this process can be reversed by removing the quinolone, adding EDTA, or mild heat treatment. Cell killing is relatively slow, and the rate of killing seems to correlate with later massive chromosomal DNA fragmentation mediated by a putative protein suicide factor, whose synthesis may be blocked by chloramphenicol. In contrast, a high concentration of fluoroquinolones such as CIP or gatifloxacin produces rapid cell death and chromosomal DNA fragmentation, processes that are not protected by chloramphenicol and thus are protein synthesis independent [6, 7]. In this case, DSBs from the cleaved complexes behave as irreversible products possibly because of the drug-mediated dissociation of topoisomerase subunits, and the DNA breaks are released from the protein constraint, thereby fragmenting the chromosome. Bactericidal antibiotics, including the quinolone norfloxacin, may induce the production of hydroxyl radicals that can cause extensive oxidative cellular damage, including secondary DNA injury, which may contribute to bacterial death [8, 9].
Quinolone resistance results essentially from target modification caused by mutations in the genes encoding the subunits of DNA gyrase and topoisomerase IV, especially in the quinolone resistance-determining region (QRDR) [10–12]. Several mutations may coexist in the same or in different subunits and may produce high-level resistance. Changes in drug permeation or overexpression of efflux pumps may also be involved and, in combination with QRDR mutations, may contribute to high-level resistance [10–12]. Several recent studies indicate that target protection through plasmid-mediated quinolone-resistance genes also may play a significant role, and its prevalence is increasing worldwide . The existence of fluoroquinolone-inactivating enzymes, like a variant of the gene that encodes aminoglycoside acetyltransferase AAC(6')-Ib, has been proposed . This enzyme variant would reduce the activity of both aminoglycosides and CIP.
Given the extended use of fluoroquinolones, especially CIP, a more thorough understanding of their activity is needed. Because chromosomal DNA fragmentation is the main mechanism that correlates with cell killing [5–7], it is the parameter of choice to assess fluoroquinolone activity. We have recently developed a kit that allows the simple and rapid assessment of the presence of fragmented DNA at the single-cell level in micro-organisms . Cells immersed in an inert microgel on a slide are lysed, stained with a highly sensitive DNA fluorochrome, and visualized with a fluorescence microscope. The nucleoids with fragmented DNA are discriminated clearly by their peripheral halo of diffused DNA fragments. The greater the fragmentation, the greater the number of DNA spots and the greater the circular surface area of diffusion evident in this assay. Here we show the significant technical value of our procedure for determining the activity of fluoroquinolones, particularly for detecting chromosomal DNA damage and repair after CIP treatment in E. coli.
Chromosomal DNA fragmentation in situ was assayed in the TG1 E. coli strain, which was grown routinely in Luria Bertani (LB) broth (1% Bacto-tryptone, 0.5% yeast extract, 0.5% NaCl) or on LB agar at 37°C in aerobic conditions. E. coli TG1 [genotype: F traD36 LacI q (lacZ)M15] proAB/supE (hsdMmcrB)5(r km k McrB) thi (lac-proAB). Cell growth in liquid cultures was evaluated by monitoring turbidity at OD600 using a spectrophotometer (Unicam 8625, Cambridge, UK). The minimum inhibitory concentration (MIC) was determined using the E-test (AB Biodisk, Solna Sweden) according to manufacturer's instructions. Viability was determined by colony counting after sequential dilutions and plating. To determine the percentage of viable cells, the number of cells seeded on the plate was counted using a cytometric camera.
Three different experiments were performed with TG1 E. coli, all in triplicate. Typical experiments are presented. In the first, several colonies of TG1 E. coli were grown overnight on LB agar plates and then resuspended in LB broth at an OD600 of 0.05 and grown to an OD600 of 0.8. The colonies were then incubated with 0, 0.003, 0.006, 0.008, 0.012, 0.02, 0.04, 0.08, 0.1, 0.5, or 1 μg/ml CIP (Sigma) in 15 ml Falcon tubes containing 4 ml of LB broth for 40 min at 37°C with aeration and shaking, and then processed to measure the chromosomal DNA fragmentation.
In the second experiment, TG1 E. coli was removed from culture in LB agar, resuspended in LB broth at an OD600 of 0.5, and treated with 1 μg/ml CIP in LB broth at 37°C with aeration and shaking. Aliquots were removed after 0, 5, 10, 15, 20, 30, and 40 min of incubation, and processed to measure DNA fragmentation. The time needed to prepare the microgel with the cells enclosed, before the slide was immersed in the lysing solution, was 8 min (see next section). In the results, this time must be added to each incubation period. To complete this experiment, TG1 E. coli were cultured in liquid LB broth at 37°C for 23 h with aeration and shaking, and the growth was monitored by measuring the turbidity (OD600). The liquid cultures started at an OD600 of 0.05. Aliquots were removed during the exponentially growing phase at 3 h (i.e., at an OD600 of 0.52) and during the stationary phase at 7 h (OD600: 1.20), 9 h (OD600: 1.52) and 23 h (OD600: 1.84). At the end of each designated time, 1 μg/ml of CIP was added directly to the aliquot, and the aliquot was incubated at 37°C for 0 and 5 min, and then processed to measure the DNA fragmentation.
In the third experiment, the micro-organisms were grown overnight on LB agar plates, resuspended in LB broth at an OD600 of 0.05, grown to an OD600 of 0.8, and then incubated with 10, 1, or 0.1 μg/ml CIP in LB broth for 40 min at 37°C. After the incubation, the CIP was removed from the medium by centrifuging the bacteria and washing in plain LB broth. The bacteria were incubated at 37°C in LB broth with aeration and shaking, and aliquots were removed at 0, 1.5, 3, 4, 5, and 24 h. For the 0.1 μg/ml dose of CIP, the bacteria were also incubated for 6 h. One aliquot was used to measure the DNA fragmentation, and another was plated on LB agar at 37°C to measure the viability after 24 h of culture. Cultures without CIP and with CIP incorporated in the new LB medium added after washing after the initial CIP treatment were included and processed along with each dose and for the various incubation times.
Bacterial strains with low CIP sensitivity
Besides the experiments with TG1, DNA fragmentation was measured in four E. coli strains whose low sensitivity to CIP and underlying mechanisms are known. These included strains with mutations in the QRDR region from GyrA and ParC . The isolates were C-15 (Ser83Leu from GyrA; CIP MIC = 0.25 μg/ml); 1273 (Ser83Leu and Asp87Tyr from GyrA; CIP MIC: 8.0 μg/ml), and 1383 (Ser83Leu and Asp87Tyr from GyrA together with Ser80Ile and Glu84Lys from ParC; CIP MIC: 128 μg/ml), and the control strain C-20 with no mutation in the QRDR region (CIP MIC: 0.007 μg/ml). The strain J53 with the plasmid-mediated quinolone-resistance gene qnrA1 (CIP MIC: 0.25 μg/ml) and its control strain J53 without the plasmid were also examined . These strains were exposed to CIP at the MIC dose, at 10× and 100× the MIC dose, and at 0.5× and 0.25× the MIC dose for 40 min at 37°C in the exponentially growing phase, and DNA fragmentation was determined.
Determination of DNA fragmentation
The Micro-Halomax® kit for fluorescence microscopy (Halotech DNA SL, Madrid, Spain) was used. A thorough description has been published previously . Essentially, an aliquot of each sample was diluted to a concentration of 5–10 million micro-organisms/ml in LB medium. The kit includes 0.5 ml snap cap microfuge tubes containing gelled aliquots of low-melting point agarose. The tube was placed in a water bath at 90–100°C for about 5 min to melt the agarose completely and then placed in a water bath at 37°C. Twenty-five microlitres of the diluted sample was added to the tube and mixed with the melted agarose. A 20 μl aliquot of the sample-agarose mixture was pipetted onto a precoated slide, and the sample was covered with a 22 mm × 22 mm coverslip. The slide was placed on a cold plate in the refrigerator (4°C) for 5 min to allow the agarose to produce a microgel with the trapped intact cells inside. The coverslip was removed gently, and the slide was immediately immersed horizontally in 10 ml of the lysing solution for 5 min at 37°C. The slide was washed horizontally in a tray with abundant distilled water for 3 min, dehydrated by incubating horizontally in cold (-20°C) ethanol of increasing concentration (70%, 90%, and 100%) for 3 min each, and air-dried in an oven.
The dried slide was incubated in a microwave oven at 750 W for 4 min, and the DNA was stained with 25 μl of the fluorochrome SYBR Gold (Molecular Probes, Eugene, OR, USA) diluted 1:100 in TBE buffer (0.09 M Tris-borate, 0.002M EDTA, pH 7.5) for 5 min in the dark.
Images were viewed under an epifluorescence microscope (Nikon E800), with a 100× objective and appropriate fluorescence filters, and the images were acquired using a high-sensitivity CCD camera (KX32ME, Apogee Instruments, Roseville, CA, USA). Groups of 16-bit digital images were obtained at each experimental time under similar conditions and stored as TIFF files. Image analysis was performed using a macro designed with Visilog 5.1 software (Noesis, Gif sur Yvette, France). This macro allows for thresholding and background subtraction, and delineates the circular area of diffusion of the DNA fragments from nucleoids. The width delimitated between the edge of the nucleoid and the circumference that limits the circular peripheral area of spreading of DNA fragments is the simplest parameter to estimate DNA fragmentation level after CIP treatment and was measured in μm. At each experimental time, 50–125 nucleoids were evaluated.
Because the data did not follow a normal distribution as ascertained by the Kolmogorov-Smirnov test, the non-parametric Mann-Whitney U test was performed to compare the groups. Significance was defined as P < 0.05.
Dose-response effect of CIP on TG1 E. coli chromosomal DNA analyzed with the Micro-Halomax® kit.
Width of dispersion (μm)
1.3 ± 0.3
1.6 ± 0.3
2.5 ± 0.4
2.1 – 3.7
3.3 ± 0.4
5.1 ± 1.0
3.8 – 5.7
7.8 ± 1.4
8.8 ± 1.6
The DNA fragmentation level did not differ between bacteria incubated with the antibiotic at room temperature or at 37°C, or with or without agitation. Interestingly, TG1 grown previously in LB broth instead of LB agar and tested in the exponentially growing phase produced the most DNA fragmentation (class IV) after 0 min; i.e., immediately after the 8 min of microgel preparing.
Evolution of DNA damage
After exposure to the highest dose (10 μg/ml), all nucleoids were extremely fragmented, i.e., class IV. The DSB repair was limited and clearly noticeable only after 4 h; 82.5% of nucleoids were of class III after 5 h. Remarkably, all the nucleoids from the bacteria observed after 24 h showed massive fragmentation (class IV). Viability was very low after 0, 1.5, 3, and 4 h, and zero after 5 and 24 h (Fig. 5a).
Immediately after incubating with the 1 μg/ml dose, all nucleoids were class IV. A higher repair level was observed than after the highest dose, predominantly class III (58.7%) after 4 h, class I (41.0%) after 5 h, and class I (47.1%) after 24 h. Apparently repaired nucleoids without diffusing DNA fragments (10.2%) were visualized after 5 h, and this increased to 22.2% after 24 h. However, the viability was very low, as in the experiment with the highest dose (Fig. 5b).
In contrast to the results at the higher doses, repair activity was evident in the cultures exposed continuously to 0.1 μg/ml of CIP for the various times (Fig. 5c); 53.0% of nucleoids were class III after 4 h, and 31% were class I and 31% class 0 after 6 h. This latter time was assessed further in this experiment. The frequency of class 0 increased from 2.3% after 4 h to 67.3% after 24 h. In all cases, viability was very low or zero. Removing the drug resulted in faster repair kinetics, predominantly of class II (76.2%) after 1.5 h and class 0 (81.0%) after 5 h (Fig. 5c). The nucleoid pattern was similar to that of the untreated control cells after 24 h. Viability was initially very low, 2–4% after 4–6 h, and increased to 56.8% after 24 h (Fig. 5c). Thus, we found no clear relationship between the extent of repair of CIP-induced DNA breakage and cell viability.
Evaluation of strains with known mechanisms of low sensitivity to CIP
DNA fragmentation levels obtained in strains of E. coli with different susceptibilities to CIP.
1.5 ± 0.3
6.7 ± 0.8
10.3 ± 2.5
Ser83Leu from GyrA
1.7 ± 0.3
6.2 ± 0.7
8.7 ± 1.1
Ser83Leu and Asp87Tyr from GyrA
1.8 ± 0.3
2.7 ± 0.4
Ser83Leu and Asp87Tyr from GyrA and Ser80Ile and Glu84Lys from ParC
1.8 ± 0.8
9.2 ± 1.2
10.4 ± 2.0
Plasmid gene J53qnrA1
1.9 ± 0.4
9.5 ± 1.3
9.8 ± 0.9
CIP-induced chromosomal DNA fragmentation was assayed in situ in E. coli using the Micro-Halomax® kit . We grew the samples in LB agar because this is simpler and is used routinely in clinical microbiology laboratories. The sample is scratched, diluted in LB broth to an OD600 of 0.05, and incubated with CIP in 4 ml of liquid LB in a 15 ml Falcon tube at 37°C with aeration. Incubation in a 1.5 ml Eppendorf tube with 24 μl of LB broth at room temperature (22°C) and without aeration does not modify the kinetics of DNA fragmentation induced by 1 μg/ml of CIP. We observed similar results in the TG1 strain and in three other E. coli-sensitive samples. Further confirmation in other sensitive strains could simplify the protocol for assessing E. coli sensitivity or resistance to CIP in the clinic.
Incubating TG1 with CIP for 40 min before technical processing produced a clear dose-response effect in chromosomal DNA fragmentation, and the damage level was similar in the different nucleoids. The effect on DNA was evident starting at the MIC dose, and DNA fragments were always visualized as spots of relatively small size, independently of the dose. The fragment size after oxolinic acid or norfloxacin treatment of E. coli has been estimated at 50 to 100 kb; i.e., the presumed size of the DNA loops of the nucleoid [18–20]. Our result suggests that the DNA fragments liberated from the nucleoid are of fairly regular size and that more fragments are released as the CIP dose increases. It also supports the possibility of clusters of preferential DNA gyrase cleavage sites . It is possible that doses smaller than the MIC could induce a small amount of DSBs, which could be spaced widely in the different domains but not cause spreading of the fragments.
In our previous report, a CIP dose of 0.012 μg/ml produced slightly more damage than in the present study . This is probably because of the harsher lysing conditions in our previous study, which may have caused additional DNA damage. This was corrected in the conditions used in our current study.
Adding 1 μg/ml of CIP to TG1 in LB broth and instantaneous processing using our technique produced just barely detectable DNA fragmentation. Taking TG1 from LB agar reduces the extent of damage. DNA damage increases progressively with incubation time, and a 30 min incubation is needed to achieve the maximum level of DNA fragmentation. Remarkably, when the bacteria came from exponentially growing cultures in LB broth, the highest DNA fragmentation level was observed immediately (0 min). These results suggest that the CIP effect on DNA is cumulative with time and that its velocity is dependent on the growing conditions. We confirmed this hypothesis by analyzing aliquots removed periodically from a batch culture incubated with 1 μg/ml CIP for 0 and 5 min. The DNA fragmentation level declined progressively as the bacteria proceed into the stationary phase.
Most E. coli cells divide uniformly in exponentially growing cultures but stop dividing when they achieve the stationary phase . Bacteria grown in LB agar should be heterogeneous with regard to the growing phase, both exponential and stationary. The MIC is an average of the bacterial sensitivity to the antibiotic, which reflects the different effect of CIP on DNA. The DNA fragmentation yield is homogeneous among the nucleoids in exponentially growing TG1 but is slower and tends to be more heterogeneous in the stationary phase. This greater heterogeneity was evident after short incubation with 1 μg/ml CIP but tended to be homogeneous after 40 min of treatment.
Pulse field gel electrophoresis shows that the norfloxacin-induced fragmentation in E. coli nucleoids is low in the stationary phase of growth . This phenomenon could reflect decreased drug uptake, increased drug efflux, downregulation of topoisomerases, or a more tightly packed nucleoid structure as demonstrated by atomic force microscopy . Using our procedure, we have also observed more compacted nucleoids in the stationary phase. The most probable explanation is the activation of multidrug transporters that exclude fluoroquinolones, which is mediated by quorum-sensing signals. In fact, the quorum-sensing transcription factor SdiA from E. coli is regulated in a density-dependent manner, and its overproduction upregulates AcrAB, which increases resistance to quinolones and other antibiotics .
The lysing solution causes protein denaturation, so theoretically, the sensitivity-resistance assay is adequate to investigate sensitivity to fluoroquinolones at the relevant doses. CIP-mediated DSBs are natively unconstrained and are considered irreversible and lethal. In the case of first-generation quinolones such as nalidixic acid, the technique would artificially unconstrain DSBs that are naturally confined in the cleaved complex. If so, both reversible non-lethal DSBs and later lethal unconstrained DSBs should be detected without but cannot be differentiated in the assay. Addition of the chelating agent EDTA seems to reverse the cleaved complex formation by quinolones , possibly because incubation with EDTA before lysis allows the resealing of the reversible DNA breaks so that only the irreversible DSBs would be detected.
CIP-induced DSBs were not totally irreversible, and a progressive repair activity with time was evident in TG1. The magnitude of DNA repair was inversely related to dose and was noticeable after a dose of 0.1 μg/ml but scarce after a dose of 10 μg/ml. This repair was evident when the antibiotic was removed after the 40 min incubation and when TG1 was exposed continuously to the low dose (0.1 μg/ml) without CIP removal. The progressive spontaneous CIP degradation or inactivation with time in culture cannot be discounted, and the effect of CIP could be smaller despite being long lasting, especially if added at a low dose.
E. coli may repair DSBs by RecA-dependent homologous recombination (HR) . CIP-induced DSBs could be processed to single-stranded DNA, a target for RecA, which promotes recombinatorial repair and induction of the SOS response through activation of the autocleavage of the LexA repressor [25, 26]. Rapid lethality is increased by the lexA Ind-allele, and recombination-deficient E. coli strains are hypersensitive to quinolones . The RecBCD nuclease/helicase also seems to be required for SOS induction by quinolones, as demonstrated with nalidixic acid . Interestingly, DSBs may also be repaired by a non-homologous end joining (NHEJ) mechanism that comprises break recognition, end processing, and ligation activities. Although E. coli lacks a NHEJ pathway, its presence has been demonstrated in mycobacteria and bacillus . Nevertheless, NHEJ deficiency caused by the loss of Ku and ligD has no effect on the sensitivity to quinolones of Mycobacterium smegmatis .
Repair of quinolone-induced DSBs probably needs more complex processing because both 5' ends of cleaved DNA are linked covalently via phosphotyrosine bonds to a topoisomerase subunit. These DNA-protein crosslinks (DPCs) could be eliminated in coordination with the nucleotide excision repair (NER) mechanism. The urvABC nuclease, which initiates the NER pathway in E. coli, may incise DPCs with or without previous proteolytic degradation of the crosslinked protein . Accordingly, NER seems to be involved in CIP-induced DNA damage, as demonstrated in deficient E. coli strains . Although both NER and HR may commit to the repair of DPCs, it has been proposed recently that DPCs with crosslinked proteins of sizes < 12–14 kDa are repaired by NER, whereas oversized DPCs are processed exclusively by RecBCD-dependent HR . If confirmed, the later mechanism should be preferred in the repair of DPCs involving topoisomerase subunits.
The repair activity was not strictly related to viability. Although the nucleoid may appear normal after repair, particularly at the low dose (0.1 μg/ml), the bacteria may not be fully viable, possibly because of the lack of total fidelity in restitution and the SOS response, resulting in an error-prone repair . Some misrepaired lesions could lead to a non-viable cell. The DNA repair experiments emphasize the importance of achieving the necessary concentrations over a prolonged time for the successful clinical effect of quinolones.
DNA repair is not cited as a mechanism of decreased sensitivity to quinolones. Nevertheless, E. coli mutants with constitutive RecA expression or defective SOS induction may survive longer . It is possible that dysfunction of certain DNA repair processes may lead to a low sensitivity to CIP, and this could increase the effect of other coexisting mechanisms of resistance. This possibility needs to be explored.
It is expected that resistance to fluoroquinolones would hinder the production of DSBs, which are slowly or rarely produced. Because DSBs appear to correlate strongly with the MIC and viability, the DNA fragmentation assay should detect resistance accurately. The preliminary study of the DNA fragmentation analysis in the four E. coli strains with low sensitivity to CIP suggests that this is the case. The 1273 strain did not show a clear effect at the MIC dose and had a lower DNA fragmentation level than that observed in other strains at the same multiple of MIC dose. This phenomenon could be related to the accumulation of multiple resistance mechanisms, such as multiple mutations in different topoisomerase subunits and in conjunction with altered outer membrane proteins and lipopolysaccharide, and increased activity of efflux systems . Since only J-53 and J-53qnrA1 strains are isogenic, the other strains could have other differences that could influence the results. Moreover, the growth inhibition may not be dependent on inhibition of the topoisomerases leading to DNA fragmentation and the possibility exists of unknown mechanisms of action.
The DNA fragmentation assay may be a simple and rapid test to evaluate the sensitivity and resistance to quinolones. We are currently performing more comprehensive assessment of different characterized CIP-resistant and CIP-sensitive E. coli strains and in clinical samples.
This work was supported by a public grant from the Xunta de Galicia 07CSA050916PR and INCITE08E1R916070ES, and by FIS PI061368.
- Appelbaum PC, Hunter PA: The fluoroquinolone antibacterials: past, present and future perspectives. Int J Antimicrob Agents. 2000, 16 (1): 5-15. 10.1016/S0924-8579(00)00192-8.PubMedView ArticleGoogle Scholar
- Emmerson AM, Jones AM: The quinolones: decades of development and use. J Antimicrob Chemother. 2003, 51 (Suppl 1): 13-20. 10.1093/jac/dkg208.PubMedView ArticleGoogle Scholar
- Champoux JJ: DNA topoisomerases: structure, function, and mechanism. Annu Rev Biochem. 2001, 70: 369-413. 10.1146/annurev.biochem.70.1.369.PubMedView ArticleGoogle Scholar
- Corbett KD, Berger JM: Structure, molecular mechanisms, and evolutionary relationships in DNA topoisomerases. Annu Rev Biophys Biomol Struct. 2004, 33: 95-118. 10.1146/annurev.biophys.33.110502.140357.PubMedView ArticleGoogle Scholar
- Drlica K, Zhao X: DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol Mol Biol Rev. 1997, 61 (3): 377-392.PubMed CentralPubMedGoogle Scholar
- Drlica K, Malik M, Kerns RJ, Zhao X: Quinolone-mediated bacterial death. Antimicrob Agents Chemother. 2008, 52 (2): 385-392. 10.1128/AAC.01617-06.PubMed CentralPubMedView ArticleGoogle Scholar
- Malik M, Zhao X, Drlica K: Lethal fragmentation of bacterial chromosomes mediated by DNA gyrase and quinolones. Mol Microbiol. 2006, 61 (3): 810-825. 10.1111/j.1365-2958.2006.05275.x.PubMedView ArticleGoogle Scholar
- Dwyer DJ, Kohanski MA, Hayete B, Collins JJ: Gyrase inhibitors induce an oxidative damage cellular death pathway in Escherichia coli. Mol Systems Biol. 2007, 3: 91-View ArticleGoogle Scholar
- Kohanski MA, Dwyer DJ, Hayete B, Lawrence CA, Collins JJ: A common mechanism of cellular death induced by bactericidal antibiotics. Cell. 2007, 130 (5): 797-810. 10.1016/j.cell.2007.06.049.PubMedView ArticleGoogle Scholar
- Hooper DC: Emerging mechanisms of fluoroquinolone resistance. Emerg Infect Dis. 2001, 7 (2): 337-41.PubMed CentralPubMedView ArticleGoogle Scholar
- Hawkey PM: Mechanisms of quinolone action and microbial response. J Antimcrob Chemother. 2003, 51 (1): 29-35. 10.1093/jac/dkg207.View ArticleGoogle Scholar
- Chen F-J, Lo H-J: Molecular mechanisms of fluoroquinolone resistance. J Microbiol Immunol Infect. 2003, 36 (1): 1-9.PubMedGoogle Scholar
- Robicsek A, Jacoby GA, Hooper DC: The worldwide emergence of plasmid-mediated quinolone resistance. Lancet Infect Dis. 2006, 6 (10): 629-640. 10.1016/S1473-3099(06)70599-0.PubMedView ArticleGoogle Scholar
- Robiseck A, Strahilevitz J, Jacoby GA, Macielag M, Abbanat D, Park CH, Bush K, Hooper DC: Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside acetyltransferase. Nat Med. 2006, 12 (1): 83-88. 10.1038/nm1347.View ArticleGoogle Scholar
- Fernández JL, Cartelle M, Muriel L, Santiso R, Tamayo M, Goyanes V, Gosálvez J, Bou G: DNA fragmentation in microorganisms assessed in situ. Appl Environ Microbiol. 2008, 74 (19): 5925-5933. 10.1128/AEM.00318-08.PubMed CentralPubMedView ArticleGoogle Scholar
- Vila J, Ruiz J, Goñi P, Jimenez de Anta M: Detection of mutations in parC in quinolone-resistant clinical isolates of Escherichia coli. Antimicrob Agents Chemother. 1996, 40 (2): 491-493.PubMed CentralPubMedGoogle Scholar
- Martínez-Martínez M, Pascual A, Jacoby GA: Quinolone resistance from a transferable plasmid. Lancet. 1998, 351 (9105): 797-799. 10.1016/S0140-6736(97)07322-4.PubMedView ArticleGoogle Scholar
- Snyder M, Drlica K: DNA gyrase on the bacterial chromosome: DNA cleavage induced by oxolinic acid. J Mol Biol. 1979, 131 (2): 287-302. 10.1016/0022-2836(79)90077-9.PubMedView ArticleGoogle Scholar
- Condemine , Smith CL: Transcription regulates oxolinic acid-induced DNA gyrase cleavage at specific sites on the E. coli chromosome. Nucleic Acids Res. 1990, 18 (24): 7389-7396. 10.1093/nar/18.24.7389.PubMed CentralPubMedView ArticleGoogle Scholar
- Hsu Y-H, Chung M-W, Li T-K: Distribution of gyrase and topoisomerase IV on bacterial nucleoid: implications for nucleoid organization. Nucleic Acids Res. 2006, 34 (10): 3128-3138. 10.1093/nar/gkl392.PubMed CentralPubMedView ArticleGoogle Scholar
- Roostalu J, Joers A, Luidalepp H, Kaldalu N, Tenson T: Cell division in Escherichia coli cultures monitored at single cell resolution. BMC Microbiol. 2008, 8: 68-10.1186/1471-2180-8-68.PubMed CentralPubMedView ArticleGoogle Scholar
- Kim J, Yoshimura SH, Hizume K, Ohniwa RL, Ishihama A, Takeyasu K: Fundamental structural units of the Escherichia coli nucleoid revealed by atomic force microscope. Nucl Acids Res. 2004, 32 (6): 1982-1992. 10.1093/nar/gkh512.PubMed CentralPubMedView ArticleGoogle Scholar
- Yang S, Lopez CR, Zechiedrich EL: Quorum sensing and multidrug transporters in Escherichia coli. Proc Natl Acad Sci USA. 2006, 103 (7): 2386-2391. 10.1073/pnas.0502890102.PubMed CentralPubMedView ArticleGoogle Scholar
- Krasin F, Hutchinson F: Repair of DNA double-strand breaks in Escherichia coli, which requires recA function and the presence of a duplicate genome. J Mol Biol. 1977, 116 (1): 81-98. 10.1016/0022-2836(77)90120-6.PubMedView ArticleGoogle Scholar
- Lewin C, Howard B, Ratcliffe N, Smith J: 4-Quinolones and the SOS response. J Med Microbiol. 1989, 29 (2): 139-144.PubMedView ArticleGoogle Scholar
- Howard BM, Pinney RJ, Smith JT: Function of the SOS process in repair of DNA damage induced by modern 4-quinolones. J Pharmacol. 1993, 45 (7): 658-662.View ArticleGoogle Scholar
- Piddock LJV, Walters RN: Bactericidal activities of five quinolones for Escherichia coli strains with mutations in genes encoding the SOS response or cell division. Antimicrob Agents Chemother. 1992, 36 (4): 819-825.PubMed CentralPubMedView ArticleGoogle Scholar
- Newmark KG, O'Reilly EK, Pohhaus JR, Kreuzer KN: Genetic analysis of the requirements for SOS induction by nalidixic acid in Escherichia coli. Gene. 2005, 356: 69-76. 10.1016/j.gene.2005.04.029.PubMed CentralPubMedView ArticleGoogle Scholar
- Pitcher RS, Brissett NC, Doherty AJ: Nonhomologous end-joining in bacteria: a microbial perspective. Annu Rev Microbiol. 2007, 61: 259-282. 10.1146/annurev.micro.61.080706.093354.PubMedView ArticleGoogle Scholar
- Stephanou NC, Gao F, Bongiorno P, Ehrt S, Schnappinger D, Shuman S, Glickman MS: Mycobacterial nonhomologous end joining mediates mutagenic repair of chromosomal double-strand DNA breaks. J Bacteriol. 2007, 189 (14): 5237-5246. 10.1128/JB.00332-07.PubMed CentralPubMedView ArticleGoogle Scholar
- Minko IG, Zou Y, Lloyd RS: Incision of DNA-protein crosslinks by UrvABC nuclease suggests a potential repair pathway involving nucleotide excision repair. Proc Natl Acad Sci USA. 2002, 99 (4): 1905-1909. 10.1073/pnas.042700399.PubMed CentralPubMedView ArticleGoogle Scholar
- Nakano T, Morishita S, Katafuchi A, Matsubara M, Horikawa Y, Terato H, Salem AMH, Izumi S, Pack SP, Makino K, Ide H: Nucleotide excision repair and homologous recombination systems commit differentially to the repair of DNA-protein crosslinks. Mol Cell. 2007, 28 (1): 147-158. 10.1016/j.molcel.2007.07.029.PubMedView ArticleGoogle Scholar
- Chenia HF, Pillay B, Pillay D: Analysis of the mechanisms of fluoroquinolone resistance in urinary tract pathogens. J Antimicrob Chemother. 2006, 58 (6): 1274-1278. 10.1093/jac/dkl404.PubMedView ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.